Vertex Shelves mRNA Drug; Cytokinetics Hits Efficacy
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Vertex Pharma shelves early‑stage mRNA cystic fibrosis drug VX‑522 after tolerability issues, despite Q1 earnings meeting consensus.
- Viridian Therapeutics announces positive top‑line Phase 3 results for elegrobart in chronic thyroid eye disease.
- Cytokinetics reports Myqorzo achieving twin efficacy goals in a study of non‑obstructive hypertrophic cardiomyopathy, improving heart‑failure symptoms and cardiovascular fitness.
- Pfizer reports first‑quarter earnings alongside partner Alkermes.
- Moderna remains a partner on the discontinued VX‑522 mRNA program.
Why it matters: Investors gain from Vertex’s on‑target Q1 earnings, while patients with thyroid eye disease and hypertrophic cardiomyopathy receive new therapeutic options; Myqorzo meeting twin efficacy goals (two endpoints) lifts market confidence in genetic heart disease pipelines.
